From: Utilization of diabetes medication and cost of testing supplies in Saskatchewan, 2001
Therapy | Number of Patients with Type 2 Diabetes | % of Total Patients with Type 2 Diabetes (n = 37625) | % of Type 2 Diabetes Patients Receiving Antidiabetic Therapy (n = 23,468) |
---|---|---|---|
Monotherapy | 12814 | 34.1 | 54.6 |
SU | 4803 | 12.8 | 20.5 |
Met | 5767 | 15.3 | 24.6 |
TZD | 32 | 0.1 | 0.1 |
Insulin | 2212 | 5.9 | 9.4 |
Oral Combination Therapy | 7493 | 19.9 | 31.9 |
SFU+Met | 6764 | 18.0 | 28.8 |
SFU+TZD | 59 | 0.2 | 0.3 |
Met+TZD | 137 | 0.4 | 0.6 |
SFU+Met+TZD | 533 | 1.4 | 2.3 |
Oral + Insulin Combination | 2151 | 5.7 | 9.2 |
SFU+Ins | 142 | 0.4 | 0.6 |
Met+Ins | 1202 | 3.2 | 5.1 |
TZD+Ins | 53 | 0.1 | 0.2 |
SFU+Met+Ins | 554 | 1.5 | 2.4 |
SFU+TZD+Ins | 15 | 0.0 | 0.1 |
Met+TZD+Ins | 88 | 0.2 | 0.4 |
SFU+Met+TZD+Ins | 97 | 0.3 | 0.4 |
Other Antidiabetic Drugs | 1010 | 2.7 | 4.3 |
No diabetes drugs | 14157 | 37.6 | - |
Total | 37625 | 100 | 100 |